Quantcast
Last updated on April 20, 2014 at 1:20 EDT

Latest BRCA1 Stories

2013-10-17 16:37:52

Researchers announced today in the journal Lancet Oncology that they are well on the way to discovering why women with the faulty genes BRCA 1 and BRCA 2, one of which was inherited by the actress Angelina Jolie, develop breast and ovarian cancer rather than other cancers. The study, carried out by researchers at the UCL Department of Women's Cancer, found that abnormal levels of female hormones in the bloodstream could be the answer. The findings have already led to more research into...

2013-10-15 08:33:34

Also Releases Results from National Harris Survey Revealing Widespread Confusion about BRCA Testing MADISON, N.J., Oct. 15, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of BRCAvantage(TM), a suite of four new lab-developed genetic tests (LDT) that identify mutations in BRCA1 and BRCA2 genes, which are associated with increased risk of inherited breast and ovarian cancers. Serving...

2013-10-15 08:29:13

Seventy-two Percent (72 percent) of Adult Women in the U.S. Have Never Heard of BRCA Testing, yet 58 Percent Would Want to Know if They Carried High-Risk Gene Mutations MADISON, N.J., Oct. 15, 2013 /PRNewswire/ -- According to the results of a recent Quest Diagnostics (NYSE: DGX) survey, seventy-two percent (72 percent) of American women age 18 and older have never heard of the BRCA test, a genetic test that can identify mutations in BRCA1 and BRCA2 genes associated with increased risk of...

2013-10-09 23:24:00

In honor of Breast Cancer Awareness Month, Fertility Centers of Illinois discusses genetic screening for breast cancer and fertility preservation during a breast cancer diagnosis. Chicago, IL (PRWEB) October 09, 2013 For some families with the BRCA1 gene mutation, the lifetime risk of breast cancer can be as high as 80 percent, with the average risk of breast cancer resulting from a BRCA1 or BRCA2 gene mutation ranging from 45 to 65 percent. Through advances in modern science, couples are...

2013-10-08 13:53:37

Technology as sensitive as standard methodology but more efficient, say researchers in the Journal of Molecular Diagnostics The recognition of a causal link between mutations in BRCA1 and BRCA2 genes and increased risk of developing breast and ovarian cancer has intensified the demand for genetic testing. Identifying mutations in these large genes by conventional methods can be time consuming and costly. A report in the November issue of the Journal of Molecular Diagnostics describes a new...

2013-10-07 23:25:11

A New York infertility treatment and research center earns a patent for a unique method of reducing the risk and spread of breast and ovarian cancer in women. New York, New York (PRWEB) October 07, 2013 The Center for Human Reproduction (CHR), a leading fertility research and treatment center in New York City, has been awarded a U.S. patent by the U.S. Patent and Trademark Office regarding use of FMR1 gene inhibitors as a method of reducing the risk of and/or spread of breast or ovarian...

2013-08-26 08:27:51

GAITHERSBURG, Md., Aug. 26, 2013 /PRNewswire/ -- GeneDx, one of the world's foremost genetic testing laboratories and a wholly-owned subsidiary of Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) has announced the launch of a comprehensive suite of genetic tests for inherited cancer, including a 26-gene panel for breast and ovarian cancer that includes BRCA1 and BRCA2 and next generation sequencing based multi-gene panels for colorectal cancer, pancreatic cancer, and endometrial...

2013-08-15 08:29:35

-- Will continue to offer fast, accurate, and affordable alternative for BRCA1/2 testing -- HOUSTON, Aug. 15, 2013 /PRNewswire/ -- Gene By Gene, Ltd. announced that it is teaming with Ambry Genetics to defend against Myriad Genetics' patent infringement lawsuits against both companies in connection with the BRCA1/2 tests being offered by Gene By Gene and Ambry Genetics. Both companies are also countersuing Myriad for violations of the Federal Antitrust Act. On June 13, 2013,...

2013-08-08 09:19:31

The global study was led by University of Melbourne and the Peter MacCallum Cancer Centre and published in the Journal of Clinical Oncology today. The study involved about 2,500 women from Europe, North America and Australia who have inherited mutations in BRCA1 or BRCA2, the breast cancer susceptibility genes, and who had been diagnosed with breast cancer. About one-third of these women were placed on tamoxifen. Tamoxifen has been used for decades to treat breast cancer and has...

2013-08-02 12:30:50

Two women have the same genetic mutation – an abnormal BRCA1 gene that puts them both at much higher-than-average risk for breast cancer – but only one woman develops the disease. Why? Michigan State University genetic scientists have begun to understand the mechanisms behind the phenomena. "It's been known for a while that genetic mutations can modify each other," explained Ian Dworkin, MSU associate professor of zoology. "And we also know that the...